# DexCom, Inc. (DXCM)

> DexCom, Inc. (DXCM) trades at $79.32 (-1.08%) as of 7:54:54 PM EST on Nov 20, 2026, +1.28% over the past month. Market cap is $29.58B, with 2.8 days to cover in short interest.

Canonical: https://massive.com/quote/dxcm
Data as of: 2026-11-21T00:54:54.872Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$79.32** -0.87 (-1.08%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$78.18** -1.14 (-1.44%)
As of 7:54:54 PM EST on Nov 20, 2026 · After hours

## Stock performance

How DexCom, Inc. (DXCM) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.08% |
| 1W | -4.81% |
| 1M | +1.28% |
| YTD | +19.51% |
| 1Y | +27.50% |
| 52-wk range | $56.72 – $92.59 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for DXCM: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $78.75 – $81.58 |
| Open | $80.48 |
| Prev close | $80.19 |
| Volume | 4.62M |
| Market cap | $29.58B |
| Shares out | 372.95M |

## Valuation and profitability ratios

Valuation and profitability ratios for DexCom, Inc.: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 29.85 |
| P/S | 5.80 |
| P/B | 11.67 |
| P/FCF | 26.93 |
| ROE | 39.1% |
| ROA | 15.9% |
| Debt/Equity | 0.49 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[DexCom, Inc. (DXCM) insider trading](https://massive.com/quote/dxcm/insider-trading.md): open-market Form 4 buys and sells by DexCom, Inc. insiders over the last 12 months.

## 8-K filings

Material corporate events DexCom, Inc. has disclosed to the SEC on Form 8-K.

- Oct 29, 2026 · [Share repurchase program](https://massive.com/quote/sec-filings/8-k/share-buybacks.md)
  “On October 29, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock, par value $0.001 per share ("Common Stock"), with a repurchase period ending no later than December 31, 2027 (the "Share Repurchase Program").”
- Sep 14, 2026 · Executive compensation change
  “In connection with Mr. Sylvain's promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the "Offer Letter") providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company's Amended and Restated 2015 Equity Incentive Plan, to participate in the Company's Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.”
- Sep 10, 2026 · Director appointment
  ““On September 10, 2026, the Board of Directors ... increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately.” “The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation Committee and the Audit Committee of the Board, effective immediately.””
- May 28, 2026 · Annual meeting results
  “On May 27, 2026, DexCom, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting")... Dexcom stockholders elected the following twelve nominees to the Company's board of directors... Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom's independent registered public accounting firm... Dexcom stockholders approved, on a non-binding advisory basis, the compensation of Dexcom's named executive officers.”
- May 15, 2026 · [Share repurchase program](https://massive.com/quote/sec-filings/8-k/share-buybacks.md)
  “On May 14, 2026, Dexcom announced that its Board of Directors authorized and approved a share repurchase program of up to $1.0 billion of Dexcom's outstanding common stock, par value $0.001 per share, with a repurchase period ending no later than June 30, 2027. In connection with the approval of the Share Repurchase Program, the Board of Directors terminated its existing share repurchase program, of which $250.0 million remained available to be repurchased under the program.”

## Dividend history and stock splits

DexCom, Inc.'s recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 4-for-1 · Jun 13, 2022

## Similar companies

Public companies in a similar business to DexCom, Inc..

- [PODD](https://massive.com/quote/podd.md) Insulet Corporation (-2.96%)
- [ABT](https://massive.com/quote/abt.md) Abbott Laboratories (-0.84%)
- [HQY](https://massive.com/quote/hqy.md) HealthEquity, Inc (-2.70%)
- [AMN](https://massive.com/quote/amn.md) AMN Healthcare Services (+3.87%)

Daily change in the latest session, 15-minute delayed.

## DXCM short interest

How heavily DXCM is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 2.8 |
| Short interest | 15.93M |
| Avg volume | 5.68M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## DXCM news

The latest news and headlines about DexCom, Inc. (DXCM).

- [Continuous Ketone Monitoring (CKM) Market Analysis and Forecast to 2036 \| Industry to Reach US$5.48 Billion as AID Integration and Dual Sensors Accelerate](https://www.globenewswire.com/news-release/2026/11/20/3407652/28124/en/continuous-ketone-monitoring-ckm-market-analysis-and-forecast-to-2036-industry-to-reach-us-5-48-billion-as-aid-integration-and-dual-sensors-accelerate.html) · GlobeNewswire Inc. · Nov 20, 2026 · positive sentiment
- [Here's Why You Should Retain DexCom Stock in Your Portfolio for Now](https://www.zacks.com/stock/news/3029250/here-s-why-you-should-retain-dexcom-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-3029250) · Zacks Investment Research · Nov 13, 2026 · neutral sentiment
- [DexCom to Launch 15-Day G7 CGM System in Canada This November](https://www.zacks.com/stock/news/3022026/dexcom-to-launch-15-day-g7-cgm-system-in-canada-this-november?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-3022026) · Zacks Investment Research · Nov 3, 2026 · positive sentiment
- [Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence](https://www.globenewswire.com/news-release/2026/11/03/3393925/0/en/continuous-glucose-monitoring-market-in-india-usd-452-9-million-opportunity-by-2032-as-digital-diabetes-care-expands-reports-mordor-intelligence.html) · GlobeNewswire Inc. · Nov 3, 2026 · positive sentiment
- [DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise](https://www.zacks.com/stock/news/3019782/dexcom-stock-up-on-q3-earnings-revenue-beat-margins-rise?cid=CS-ZC-FT-analyst_blog|earnings_article-3019782) · Zacks Investment Research · Oct 30, 2026 · positive sentiment

## About DexCom, Inc.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 11.1K |
| Listed | Apr 14, 2005 |

[Company website](https://www.dexcom.com)

## FAQ

### What is the DexCom, Inc. (DXCM) stock price today?

DexCom, Inc. (DXCM) is trading at $79.32 (-1.08% on the day) as of 7:54:54 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is DexCom, Inc.?

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet…

### What is the short interest in DXCM?

As of Oct 30, 2026, DXCM has 15.93M shares short and 2.8 days to cover.

### What exchange is DXCM listed on?

DexCom, Inc. (DXCM) trades on Nasdaq in USD, in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry.

## Live data

Prices here are 15-minute delayed. For real-time DXCM quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=DXCM`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [DexCom, Inc. (DXCM) insider trading](https://massive.com/quote/dxcm/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
